Abemaciclib dose escalation for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests whether women with early-stage HR+/HER2- breast cancer can safely take a higher dose of the drug abemaciclib (Verzenio) after surgery. The goal is to keep the treatment as strong as possible while managing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer that is hormone receptor positive (HR+) and HER2 negative.
- Your doctor has already prescribed abemaciclib (Verzenio) after surgery.
- You are able to go about your daily activities with little to no help (ECOG status 0 to 2).
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control.
- You do not have a chronic history of diarrhea or an active infection requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a targeted therapy (abemaciclib) to standard chemotherapy before surgery can shrink tumors and improve outcomes in hormone-positive, HER2-negative early breast cancer. It also uses a genetic test (Oncotype DX) to help guide surgical choices.
This study looks at how the body handles the drug abemaciclib, and how it relates to severe diarrhea, which is a common side effect. It is for people with high-risk, hormone receptor positive breast cancer who have already had surgery. The goal is to better understand and possibly manage diarrhea, so you can stay on treatment.
This trial tests a drug called abemaciclib for people with early-stage, hormone-receptor-positive, HER2-negative breast cancer who still have cancer DNA in their blood after completing standard treatment. It aims to see if taking this drug can reduce the chance of cancer coming back.
This trial tests whether a targeted therapy (abemaciclib) combined with focused radiation (SBRT) to a bone tumor can help people with advanced breast cancer. It is for patients whose cancer is hormone receptor positive and HER2 negative, and who will continue abemaciclib after radiation.
This trial tests whether adding a targeted drug (abemaciclib) to standard treatment helps prevent breast cancer from coming back again after a local recurrence in women with HR-positive, HER2-negative breast cancer.
This Phase 1/2 trial tests whether combining abemaciclib with bicalutamide can slow or shrink HER2-negative, androgen receptor–positive (AR-positive) metastatic breast cancer. It mainly looks at safety and side effects, and also whether the combination can help patients with this type of breast cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.